+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 4 Actively Recruiting clinical trials

C

Actively Recruiting

Researchers are investigating the use of psilocybin-assisted psychotherapy PAP to prevent relapse in adults with alcohol use disorder AUD who also experience depressive symptoms. This study compares the effects of high-dose versus low-dose psilocybin in reducing relapse risk over six months. The study builds on earlier pilot findings suggesting psilocybin may reduce drinking days and cravings, offering a potentially faster-acting option than traditional antidepressants for individuals with AUD and depression. Participants receive two doses of psilocybin, either a high dose of 25 mg or a low dose of 3 mg, administered three weeks apart. The study uses a randomized, parallel design, with participants assigned to either the high-dose or low-dose group to evaluate differences in relapse prevention. A third dose may be offered later based on participant request and study assessments. During the study, participants are closely monitored with scheduled assessments of drinking behavior, craving, depressive symptoms, anxiety, quality of life, and other psychological factors. Various tests and questionnaires are administered at baseline and multiple follow-up points up to 51 weeks. Safety and tolerance of psilocybin are also evaluated. The total participation duration extends to about one year, allowing detailed observation of relapse rates and related outcomes.

Age: 18Years +All GendersPhase 3
8 locations
P

Actively Recruiting

Researchers are conducting a multicenter, phase 3, open-label study to evaluate treatments for patients with newly diagnosed Multiple Myeloma who are eligible for autologous stem cell transplantation ASCT. The study compares the effects of an experimental combination of elranatamab and lenalidomide against the current standard of care, including chemotherapy, ASCT, and maintenance therapies. The purpose is to assess if these new treatment approaches improve outcomes such as minimal residual disease MRD negativity and progression-free survival. Participants will first undergo induction therapy with four cycles of D-VRd daratumumab, bortezomib, lenalidomide, dexamethasone. Then, they will be randomly assigned to one of two consolidation therapies either standard treatment with high-dose chemotherapy and ASCT followed by D-VRd consolidation, or an experimental consolidation with elranatamab and lenalidomide. After consolidation, patients are re-randomized into maintenance therapy groups receiving either daratumumab plus lenalidomide or elranatamab monotherapy for approximately two years, with treatment adjustments based on MRD status. Throughout the study, participants will have scheduled visits for treatment administration, monitoring, and various assessments including blood tests, imaging, and quality of life questionnaires. Researchers will measure key outcomes such as MRD negativity rates, progression-free survival, overall survival, safety, and tolerability over several years. The study also tracks health-related quality of life and adverse events during induction, consolidation, and maintenance phases, with follow-up extending up to 11 years.

Age: 18Years - 69YearsAll GendersPhase 3
69 locations
S

Actively Recruiting

Healthy Volunteer

Human papillomaviruses HPV are common contagious viruses, with about 70% of men and women expected to be infected during their lifetime. Despite vaccination recommendations since 2007 for girls and since 2021 for young people aged 11 to 14, vaccination rates remain low, especially in the Auvergne Rhne Alpes region. This regional study aims to evaluate the effect of a primary prevention program on increasing HPV vaccination rates among adolescents aged 11 to 17. The study compares two groups one receiving no intervention and the other receiving an HPV primary prevention intervention. The intervention includes a one-week interactive exhibition titled Taking care of yourself and preventing cancer risks, a classroom presentation on HPV delivered by a healthcare team, and distribution of prevention materials. The presentation features key information about HPV, its transmission, affected groups, possible consequences, and protection methods, including interactive discussions and games. Participants will be assessed at the start and six months later for HPV vaccination status, health literacy, and knowledge about HPV and cancer risks. Acceptability of the intervention is evaluated at the end of the one-week program. The study involves students and teachers at public middle and high schools, with follow-up over six months to monitor vaccination uptake and related knowledge improvements.

Age: 11Years - 17YearsAll GendersPhase Not Applicable
1 location
I

Actively Recruiting

This research aims to improve preventive health practices in primary care by supporting changes in diet, physical activity, and sedentary behavior among adults. The study focuses on patients who are less motivated to change these behaviors and evaluates a tailored training program for general practitioners GPs in France. The goal is to enhance brief opportunistic interventions during routine consultations to reduce chronic condition risks linked to unhealthy behaviors. The study compares two groups one where GPs receive specialized training in Healthy Conversation Skills to support patients behavior change, and a control group where GPs continue usual care without this training. The training includes online courses, workshops, follow-up coaching, and patient support materials adapted from the Making Every Contact Count program. Trained GPs provide brief behavior change support during routine visits. Participants are adults registered with participating practices who have low motivation to change diet or exercise habits. Researchers will assess motivation to change behaviors using specific scales two weeks after consultation. The study monitors patients readiness to adopt healthier behaviors and gathers data on the programs implementation and effectiveness. Participation involves routine care visits and follow-up assessments, with the study running until July 2029.

Age: 18Years +All Genders
4 locations